Clinical Trial Search

Primary: Proportion of Subjects Alive and Off of Oxygen at Day 14 — 1; 1 Participants

Primary: Phase Ib: Percentage of Participants With Adverse Events, as a Measure of Safety — 6; 12; 12; 13 Participants

Primary: Safety: Incidence of Post Chemotherapy Surgical Debulking — 15 Participants

Primary: For Dose Escalation: Incidence of Dose-limiting Toxicities (DLT) to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ZEN003694 in…

Primary: Time to Relapse (TTR) — 12.14 months

Primary: Maximum Observed Change From Pretreatment Baseline in the Standardized Photosensitivity Range (SPR) — -0.2; -4.4; -5.2; -4.8 Number of frequency steps

Primary: Percentage of Subjects That Reach Pathological Downstaging (Response) at the Time of Cystectomy — 56 percentage of patients with response

Primary: Dose-limiting Toxicity (DLT) — 0; 0; 0; 0 Participants

Primary: Complete Response Rate — 2; 8 Participants

Primary: Median Overall Survival (OS) — 7.1 Months

Primary: The Percentage of Patients Alive and Without Progression at 6 Months Following the Initiation of Treatment — 59.4; 21.2 percentage of participants

Primary: Number of Subjects Who Achieved FIX Level ≥12% — 3; 4; 4; 4 Participants

Primary: Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF) — 13 Participants

Primary: Relative Dose Intensity (RDI) Per Cohort — 97.9; 89.6 percentage of dose

Primary: Percentage of Participants Who Achieved Clinical Remission at Week 24 — 25.0; 25.0; 16.7 percentage of participants